Zanidatamab, CLDN18.2-Directed ADCs, Ivonescimab, and KRAS Inhibitor Data Headline Key GI Cancer Findings From ESMO 2026

Updated survival data with zanidatamab-hrii (Ziihera)-based regimens from the phase 3 HERIZON-GEA-01 trial (NCT05152147), findings with the claudin 18.2 (CLDN18.2)-directed antibody-drug conjugates (ADCs) arcotatug tavatecan and sonesitatug vedotin from the phase 3 G-HOPE-001 (NCT06238843) and CLARITY-Gastric 01 (NCT06346392) trials, overall survival (OS) results with ivonescimab from the phase 3 HARMONi-GI1 trial (NCT06591520), and early data with the KRAS G12D inhibitor INCB161734 were among the most closely watched gastrointestinal (GI) cancer data and trends presented at the 2026 ESMO Congress.